Skip to main content

Table 3 Treatment-related adverse events (AEs) observed during the therapeutic Part

From: A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

 

Arm A - 370 MBq

Arm B - 1110 MBq

N = 3

N = 5

Patients

Patients

 

N

%

N

%

All treatment-related AEs

3

(100.0%)

4

(80.0%)

Lymphopenia

3

(100.0%)

4

(80.0%)

Anemia

3

(100.0%)

3

(60.0%)

Leucopenia

1

(33.3%)

4

(80.0%)

Asthenia

2

(66.7%)

2

(40.0%)

Hemoptysis

1

(33.3%)

3

(60.0%)

Thrombopenia

1

(33.3%)

3

(60.0%)

Neutropenia

0

(0.0%)

3

(60.0%)

Anorexia

2

(66.7%)

0

(0.0%)

Creatinine increased

0

(0.0%)

2

(40.0%)

Hypokalemia

1

(33.3%)

1

(20.0%)

Nausea

1

(33.3%)

1

(20.0%)

Hypoalbuminemia

1

(33.3%)

0

(0.0%)

Hypophosphatemia

0

(0.0%)

1

(20.0%)

Hypoxemia

0

(0.0%)

1

(20.0%)

Vomiting

1

(33.3%)

0

(0.0%)

Weight loss

1

(33.3%)

0

(0.0%)

All treatment-related AE ≥ Grade 3

1

(33.3%)

4

(80.0%)

Lymphopenia

0

(0.0%)

3

(60.0%)

Thrombopenia

1

(33.3%)

2

(40.0%)

Anemia

1

(33.3%)

1

(20.0%)

Neutropenia

0

(0.0%)

2

(40.0%)

Asthenia

1

(33.3%)

0

(0.0%)

Hemoptysis

0

(0.0%)

1

(20.0%)

Hypoxemia

0

(0.0%)

1

(20.0%)

Leucopenia

0

(0.0%)

1

(20.0%)